{
    "symbol": "CYCC",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-09 20:06:03",
    "content": " With regard to our second oral fadra study, 065-102 in patients with acute myeloid leukemia and myelodysplastic syndrome, we are enrolling patients at dose level four, which is 100 milligrams BID Monday -Friday on weeks one through three on a 28-day cycle. Net cash used in operating activities was $15.7 million for the nine months ended September 30, 2022 and compared to $14 million for the same period of 2021. Research and development or R&D expenses were $4.4 million for the three months ended September 30 2022, as compared to $4.2 million for the same period in 2021. The R&D expenses relating to fadraciclib were $2.5 million for the three months ended September 30, 2022 as compared to $3.3 million for the same period in 2021. R&D expenses related to CYC140 were $1.7 million for the three months ended September 30, 2022 as compared to $0.7 million for the same period in 2021 due clinical trial costs associated with the 140-101 Phase 1/2 study. General and administrative expenses for the three months ended September 30, 2022 were $2.1 million compared to $1.8 million for the same period of the previous year due to an increase in professional and legal costs. Total other income net for the three months ended September 30 2022 was $0.4 million compared to $13,000 for the same period of the previous year. The increase of $0.3 million for the three months ended September 30, 2022 is primarily related to foreign exchange gains. United Kingdom research and development tax credits were $1 million for each of the three months ended September 30, 2022 and September 30, 2021 and are directly correlated to qualifying research and development expenditure. Net loss for the three months ended September 30, 2022 was $5.1 million compared to $5 million for the same period in 2021."
}